Biogen Inc. is a biotechnology company specialized in the treatment of neurological diseases. It researches, develops, and markets therapies for a range of diseases including Alzheimer’s disease, hemophilia, multiple sclerosis, spinal muscular atrophy, plaque psoriasis, leukemia, rheumatoid arthritis, lymphoma, neurocognitive disorders, and pain.
225 Binney Street, Cambridge, MA 02142
CategoryBiotech & Pharmaceuticals
Taking meaningful action to protect the environment and impact health and equity. 3% Absolute reduction in scope 1 and 2 emissions from a 2019 baseline year. 100% of facilities maintain fair share water withdrawal. 97% diversion of waste from landfill. As a company that cares deeply about health and equity, we continue to make strides in reducing the environmental impact of our products and operations, addressing the link between planetary and human health. In 2022, we introduced Principles of Sustainable Drug Development and completed multiple product life cycle assessments (LCAs). In our operations, we maintained 100% renewable electricity, expanded our electric vehicle (EV) program to 15 countries and 81% of our labs achieved My Green Lab certification.We believe everyone deserves access to a supportive health ecosystem that enables them to live the healthiest, fullest life possible. That’s one reason why we work fearlessly to promote access and health equity. Our strategies include increasing representation of diverse patient populations in clinical trials and throughout the development process, providing medicines to those in need, and addressing affordability and pricing. Our multi-pronged strategy helps us increase our organizational understanding of the challenges faced by patients on their health journey. Acting on what we learn, we collaborate with a range of stakeholders and work to promote education on the importance of accurate and early diagnosis, support underserved and underrepresented communities with information and resources, identify and eliminate barriers to appropriate care, and reduce stigma and bias around various disease areas, with efforts ranging from road shows and community events to collaborations with patient advocacy groups. We also engage with key medical experts (KMEs) across our product portfolio.Guided by our purpose, Biogen is committed to progress on environmental, social and governance (ESG) issues. Following our Corporate Governance Principles, ESG oversight is formally embedded in our Board of Directors’ governance principles and includes a regular review of our ESG strategy and short- and long-term goals. Our Board regularly reviews its composition and aims to ensure it incorporates the experience, skills and diversity necessary for effective, independent oversight. The Board is made up of Directors with diverse skills and qualifications, including a range of professional and personal backgrounds as well as ESG experience. In 2022, Biogen once again tied a portion of our employees’ and executive officers’ compensation to advancing our ESG strategy. Biogen specializes in therapies for neurological and neurodegenerative diseases. Its focus on innovative treatments contributes to its financial stability. Biogen generates revenue from the sales of therapies for diseases such as multiple sclerosis and Alzheimer’s. Biogen’s research and development efforts drive its financial performance and impact by addressing critical neurological health needs. The company’s therapies enhance patient outcomes in the field of neurology, impacting both the medical community and patients.Biogen is committed to supporting internationally recognized fundamental human rights activities and initiatives. At Biogen, we are committed to upholding human rights and ensuring that modern slavery (in all its forms) is not tolerated within our global business or our supply chain.